| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.052 | 0.09 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.061 | 0.09 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.09 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.053 | 0.09 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.046 | 0.1 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.1 |